270 related articles for article (PubMed ID: 15606349)
1. Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
Holmberg LA; Sandmaier BM
Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
[TBL] [Abstract][Full Text] [Related]
3. Technology evaluation: Theratope, Biomira Inc.
Morse MA
Curr Opin Mol Ther; 2000 Aug; 2(4):453-8. PubMed ID: 11249777
[TBL] [Abstract][Full Text] [Related]
4. Theratope vaccine (STn-KLH).
Holmberg LA; Sandmaier BM
Expert Opin Biol Ther; 2001 Sep; 1(5):881-91. PubMed ID: 11728222
[TBL] [Abstract][Full Text] [Related]
5. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
[TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines, a critical review--Part II.
Mitchell MS
Curr Opin Investig Drugs; 2002 Jan; 3(1):150-8. PubMed ID: 12054066
[TBL] [Abstract][Full Text] [Related]
8. Cancer vaccine THERATOPE- Biomira.
Adis International Ltd
Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
MacLean GD; Reddish MA; Koganty RR; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
[TBL] [Abstract][Full Text] [Related]
10. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
Miles D; Papazisis K
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S134-8. PubMed ID: 12620150
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
MacLean GD; Miles DW; Rubens RD; Reddish MA; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):309-16. PubMed ID: 8877724
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of the STn-KLH vaccine (Theratope).
Ibrahim NK; Murray JL
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S139-43. PubMed ID: 12620151
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination.
Freire T; Lo-Man R; Piller F; Piller V; Leclerc C; Bay S
Glycobiology; 2006 May; 16(5):390-401. PubMed ID: 16449349
[TBL] [Abstract][Full Text] [Related]
14. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
15. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
16. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.
Emens LA; Reilly RT; Jaffee EM
Endocr Relat Cancer; 2005 Mar; 12(1):1-17. PubMed ID: 15788636
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
19. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
20. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen.
Zhang S; Walberg LA; Ogata S; Itzkowitz SH; Koganty RR; Reddish M; Gandhi SS; Longenecker BM; Lloyd KO; Livingston PO
Cancer Res; 1995 Aug; 55(15):3364-8. PubMed ID: 7614472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
